Last mentioned: Mar 24, 2026
Operations Online
New facilities expected to begin full-scale production of neuroscience and metabolic drugs.
Operational Launch
The new facilities are expected to come online and begin API production.
Operational Launch
The North Chicago facilities are expected to begin full-scale API production.
Operational Launch
New facilities expected to come online to support next-gen drug production.
Construction Start
Anticipated groundbreaking for the two new manufacturing plants.
Construction Start
Groundbreaking expected for the two new advanced manufacturing facilities.
Construction Start
Groundbreaking expected for the two new advanced manufacturing sites.
Construction Start
Anticipated ground-breaking for the two new advanced manufacturing sites.
Earnings Release
Company reports Q4 beat and issues bullish 2026 revenue guidance.
TD Cowen Conference
AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
DOJ Legal Support
The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.
RBC Coverage Launch
RBC Capital Markets initiates coverage with an Outperform rating, citing durable growth.
Expansion Announcement
AbbVie unveils $380 million investment for North Chicago API manufacturing.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
Manufacturing Expansion
AbbVie announces $380M investment for North Chicago API facilities.
Manufacturing Expansion
AbbVie announces $380 million investment for North Chicago API facilities.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and manufacturing over the next decade.
$100B Pledge
AbbVie commits to $100 billion in U.S. R&D and capital investments over the next decade.
Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
A new screening of high-conviction dividend stocks highlights leaders across healthcare, energy, and technology sectors. As investors seek defensive positioning, these seven companies represent a blend of dividend growth and capital preservation potential.
Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
A comparative analysis of Savara and Enanta Pharmaceuticals reveals a stark contrast between a de-risked rare disease specialist and a virology firm navigating a pipeline transition. While Savara gains momentum from Phase 3 success in aPAP, Enanta continues to leverage its royalty-based financial foundation to fund high-stakes antiviral trials.
AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.
AbbVie has committed $380 million to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long investment pledge. The project aims to localize the production of active pharmaceutical ingredients and is expected to create hundreds of specialized engineering and technical roles by 2029.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.